In addition to its role as a biomarker in GC, the downregulation of GPR155 was reported as significantly associated with more aggressive HCC phenotypes including high preoperative α-fetoprotein, poor differentiation, serosal infiltration, vascular invasion, and advanced disease stage (Umeda et al., 2017). Here, GPR155 is linked to gastric cancer.